ARCHIVES

Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

Kansas Gov. Sebelius Nominated For HHS

March 6, 2009

NCI Raises New Questions About Duke Genomics Research, Cuts Assay From Trial

May 14, 2010

Two activists Are Appointed To Complete NCAB

May 31, 1991

In Brief: Lobuglio Named Alabama Comprehensive Center Director; NCI FY 1983 Funds Will Be $983.6 Million

January 7, 1983

In Brief: William Roper To Head Health Research Center; Announcement Of New NIH director Is Imminent

July 2, 1993

Increase In DCCR Grants May Not Be Possible Without Decreasing Quality, Committee Told

July 28, 1978